Here's what Cramer had to say about callers' stocks during the "Lightning Round":
Wendy's Company (WEN): "I think Wendy's is cheap and it's a buy here."
RR Donnelley (RRD): "This used to be a great growth company but I don't see any growth."Sprint Nextel (S): "Don't let Sprint go. It's reasonable for it to pull back, but if that happens you buy more. Sprint goes higher." Lennar (LEN): "Buy half here and the rest on a pullback. " Rovi Corporation (ROVI): "No, no. They failed to deliver and I don't like the growth prospects there." Bank of America (BAC): "It's not my favorite. They don't have any earnings momentum. It'll come back eventually." Opko Health (OPK): "It has not acted well. I need to hear from their CEO again. Otherwise, don't buy. "
Weeding Through PossibilitiesIn the "Executive Decision" segment, Cramer spoke with Charles Foster, chairman, president and CEO of Charles River Labs (CRL), a company that helps big pharma weed through thousands of drug possibilities to find the chosen few with high probabilities of success. Foster explained that Charles River changes the value proposition for big drug makers by saving them both time and money through outsourcing much of their pre-clinical testing. In times past, he said, if a drug maker had eight drug variants, they'd develop all eight. Now the process must be refined to a single candidate as it's simply too costly to develop more than one. Charles River aims to partner with the majority of major drug makers, said Foster, and outsource the majority of their pre-clinical testing work. He predicted growth for the company in the mid-single digits for the next three years, with profit margins hovering around 20%. Cramer said while it's often hard to invest in biotech companies, Charles River lowers the risk by serving all of them. He is also a big fan of the company's share buyback program, which has already retired 28% of it's outstanding shares.
No Huddle OffenseIn his "No Huddle Offense" segment, Cramer answered the question on every investor's mind: Does the selection of Rep. Paul Ryan as running mate to presumptive Republican presidential candidate Mitt Romney matter to the markets? In a word, no.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV